Gilead Sciences stock reaches EUR 144.36 ahead of Q3 results

Published on 10/29/2026 at 17:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Gilead Sciences stock is moving higher ahead of the company’s scheduled third-quarter update. New research details broaden the focus beyond the core HIV franchise.

Key points before results

Gilead has scheduled its third-quarter 2026 results and guidance for after the U.S. market close on October 29.
New IDWeek material covers HIV treatment, twice-yearly PrEP adoption and an investigational herpes program.
The company enters the update with a strong HIV franchise and an expanded development pipeline.

Gilead Sciences, US3755581036, Illustration mit AI erstellt.

Gilead Sciences stock reached EUR 144.36 in Lang & Schwarz trading at 17:06 Berliner time on October 29, 2026. That compares with EUR 141.71 at 18:06 CEST on October 27 in the latest relevant own report, an increase of 1.87 percent. The comparison is separate from any Xetra day-to-day move.

The immediate scheduled event is Gilead’s third-quarter 2026 results and guidance, due after the U.S. market close on October 29. In its October 15 announcement, the company said management would discuss the quarter and provide a business update during a webcast at 4:30 p.m. Eastern Time.

Pipeline breadth adds context

A separate Gilead research update, dated October 19 and updated October 26, detailed 28 presentations at IDWeek 2026. The program included further analyses of Bixlenvo in virologically suppressed adults with HIV, early real-world adoption data for twice-yearly Yeztugo PrEP and Phase 1b findings for investigational GS-1179 in recurrent genital herpes.

That material gives investors additional pipeline context before the earnings release. It also shows how Gilead is pursuing both treatment and prevention opportunities while maintaining a broad antiviral development effort.

Operating base remains central

Gilead’s second-quarter transcript showed base-business sales of USD 7.6 billion, up 10 percent year over year. Management raised its full-year HIV growth outlook to 9 to 10 percent from 8 percent, citing Biktarvy, Yeztugo and Descovy. The same update put full-year base-business sales guidance at USD 29.8 billion to USD 30.1 billion.

For investors, the third-quarter figures will help test whether commercial momentum can support the company’s expanded pipeline and acquisition-related investment. The latest quote puts Gilead’s market value at USD 200.079 billion, while the reported 52-week range is USD 114.02 to USD 163.98.